Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID ‐19 vaccination
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.52081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Ilya Kister und 19 weiteren Autor:innen. Beteiligte Einrichtung: NYU Multiple Sclerosis Comprehensive Care Center, Department of Neurology, New York University Grossman School of Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Monoclonal, Humanized, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Genentech.
Abstract (Originalsprache)
Objectives
(1) To plot the trajectory of humoral and cellular immune responses to the primary (two‐dose) COVID‐19 mRNA series and the third/booster dose in B‐cell‐depleted multiple sclerosis (MS) patients up to 2 years post‐vaccination; (2) to identify predictors of immune responses to vaccination; and (3) to assess the impact of intercurrent COVID‐19 infections on SARS CoV‐2‐specific immunity.
Methods
Sixty ocrelizumab‐treated MS patients were enrolled from NYU (New York) and University of Colorado (Anschutz) MS Centers. Samples were collected pre‐vaccination, and then 4, 12, 24, and 48 weeks post‐primary series, and 4, 12, 24, and 48 weeks post‐booster. Binding anti‐Spike antibody responses were assessed with multiplex bead‐based immunoassay (MBI) and electrochemiluminescence (Elecsys®, Roche Diagnostics), and neutralizing antibody responses with live‐virus immunofluorescence‐based microneutralization assay. Spike‐specific cellular responses were assessed with IFNγ/IL‐2 ELISpot (Invitrogen) and, in a subset, by sequencing complementarity determining regions (CDR)‐3 within T‐cell receptors (Adaptive Biotechnologies). A linear mixed‐effect model was used to compare antibody and cytokine levels across time points. Multivariate analyses identified predictors of immune responses.
Results
The primary vaccination induced an 11‐ to 208‐fold increase in binding and neutralizing antibody levels and a 3‐ to 4‐fold increase in IFNγ/IL‐2 responses, followed by a modest decline in antibody but not cytokine responses. Booster dose induced a further 3‐ to 5‐fold increase in binding antibodies and 4‐ to 5‐fold increase in IFNγ/IL‐2, which were maintained for up to 1 year. Infections had a variable impact on immunity.
Interpretation
Humoral and cellular benefits of COVID‐19 vaccination in B‐cell‐depleted MS patients were sustained for up to 2 years when booster doses were administered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- NYU Multiple Sclerosis Comprehensive Care Center, Department of Neurology, New York University Grossman School of Medicine, New York, New York, USA.
- Laura and Isaac Perlmutter Cancer Center and Department of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
- Rocky Mountain MS Center, University of Colorado School of Medicine, Aurora, Colorado, USA.
- Genentech, Inc., South San Francisco, California, USA.
- Adaptive Biotechnologies, Seattle, Washington, USA.
- NYU Langone Vaccine Center and Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.
ORCID-Profile: Ilya Kister, Tamar E Bacon
Förderung
- NIAID NIH HHS
- Genentech
Zitieren
APA
Kister, I., Curtin, R., Piquet, A. L., Borko, T., Pei, J., Banbury, B. L., Bacon, T. E., Kim, A., Tuen, M., Velmurugu, Y., Nyovanie, S., Selva, S., Samanovic, M. I., Mulligan, M. J., Patskovsky, Y., Priest, J., Cabatingan, M., Winger, R. C., Krogsgaard, M., & Silverman, G. J. (2024). Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID ‐19 vaccination. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52081
Vancouver
Kister I, Curtin R, Piquet AL, Borko T, Pei J, Banbury BL, et al. Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID ‐19 vaccination. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52081
BibTeX
@article{Kister2024,
author = {Kister, Ilya and Curtin, Ryan and Piquet, Amanda L and Borko, Tyler and Pei, Jinglan and Banbury, Barbara L and Bacon, Tamar E and Kim, Angie and Tuen, Michael and Velmurugu, Yogambigai and Nyovanie, Samantha and Selva, Sean and Samanovic, Marie I and Mulligan, Mark J and Patskovsky, Yury and Priest, Jessica and Cabatingan, Mark and Winger, Ryan C and Krogsgaard, Michelle and Silverman, Gregg J},
title = {Longitudinal study of immunity to SARS‐CoV2 in ocrelizumab‐treated MS patients up to 2 years after COVID ‐19 vaccination},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.52081}
}
EUVIMED